Series C · Biotech · Cambridge, United Kingdom · Founded 2013 · 100+ employees
Nuclera is a Cambridge-based biotech company that has developed the eProtein Discovery platform, a benchtop system that accelerates protein expression and purification workflows, producing milligrams of high-quality proteins in under 48 hours versus traditional methods that can take months or years. The company recently extended its Series C funding to €74 million ($87 million), led by Elevage Medical Technologies, to integrate full-format antibody expression and binding validation capabilities. Nuclera's technology combines cell-free protein synthesis, digital microfluidics, and multiplex screening to enable rapid access to challenging proteins, with installations at leading academic institutions and biotech companies globally. The company was selected for the prestigious TechNation Future Fifty 2024 cohort and has partnerships with Google Cloud's AlphaFold2 and AI companies to accelerate drug discovery by up to 20x.